PB1776 REAL WORLD DATA OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF ADULT PATIENTS WITH DE NOVO CORE‐BINDING FACTOR ACUTE MYELOID LEUKEMIA

• Published in: HemaSphere 2019-06, Vol.3 (S1), p.815-n/a
• Main Authors: Mirgh, S.P., Kapoor, J., Garg, A., Khushoo, V., Mohan, B., bothra, S., Agrawal, N., Ahmad, R., Bhurani, D.
• Format: Article
• Language: English
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1097/01.HS9.0000565612.86445.02

Background: Core binding factor acute myeloid leukemia (CBF‐AML) are responsible for approximately 20% of all adult acute myeloid leukemia. They are considered to have a relatively good prognosis, and traditionally do not need consolidation with allogenic stem cell transplant in first remission. CBF‐AML data from India has been rarely reported. Aims: The purpose of this study was to study the clinical characteristics and survival outcomes in newly diagnosed adults with de‐novo CBF‐AML. Methods: We conducted a retrospective analysis of 29 patients diagnosed with core binding factor acute myeloid leukemia who presented to our institution over a period of six years (2013‐2018). Probabilities of survival were computed using Kaplan meier method and univariate analysis was done using log rank method. Results: We found 29 patients diagnosed with CBF‐AML. Median age of patients was 40years (range 15 to 70). Fatigue was the most common symptom (n = 19), followed by fever (n = 15), bleeding (n = 7) and extramedullary disease (n = 2). Mean duration of symptoms were 7 weeks. 41% patients (n = 12) had splenomegaly at presentation. More than two‐third patients (n = 20) had ECOG performance status 0‐1 at presentation. On cytogenetics, inv16 was found in 27.5% patients (n = 8), and t(8;21) in 65% (n = 19), whereas 2 patients had both. Intriguingly, two third patients with inv16 had monocytosis and abnormal promonocytes in peripheral smear at presentation. 55% (n = 16) had elevated LDH. Majority of patients presented with anemia (Hb